全文获取类型
收费全文 | 59784篇 |
免费 | 6367篇 |
国内免费 | 4121篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 1611篇 |
妇产科学 | 166篇 |
基础医学 | 4320篇 |
口腔科学 | 68篇 |
临床医学 | 5377篇 |
内科学 | 20400篇 |
皮肤病学 | 155篇 |
神经病学 | 290篇 |
特种医学 | 2521篇 |
外国民族医学 | 15篇 |
外科学 | 7607篇 |
综合类 | 11388篇 |
现状与发展 | 22篇 |
预防医学 | 2300篇 |
眼科学 | 32篇 |
药学 | 6061篇 |
35篇 | |
中国医学 | 4633篇 |
肿瘤学 | 3256篇 |
出版年
2024年 | 72篇 |
2023年 | 1146篇 |
2022年 | 1518篇 |
2021年 | 2374篇 |
2020年 | 2554篇 |
2019年 | 2171篇 |
2018年 | 2096篇 |
2017年 | 2401篇 |
2016年 | 2946篇 |
2015年 | 2672篇 |
2014年 | 4204篇 |
2013年 | 4134篇 |
2012年 | 3677篇 |
2011年 | 4072篇 |
2010年 | 3164篇 |
2009年 | 3064篇 |
2008年 | 3082篇 |
2007年 | 3061篇 |
2006年 | 3060篇 |
2005年 | 2520篇 |
2004年 | 1939篇 |
2003年 | 1746篇 |
2002年 | 1562篇 |
2001年 | 1426篇 |
2000年 | 1173篇 |
1999年 | 948篇 |
1998年 | 877篇 |
1997年 | 761篇 |
1996年 | 684篇 |
1995年 | 630篇 |
1994年 | 596篇 |
1993年 | 485篇 |
1992年 | 465篇 |
1991年 | 371篇 |
1990年 | 337篇 |
1989年 | 285篇 |
1988年 | 256篇 |
1987年 | 210篇 |
1986年 | 186篇 |
1985年 | 203篇 |
1984年 | 172篇 |
1983年 | 113篇 |
1982年 | 142篇 |
1981年 | 125篇 |
1980年 | 103篇 |
1979年 | 97篇 |
1978年 | 89篇 |
1977年 | 76篇 |
1976年 | 86篇 |
1975年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
肠易激综合征(IBS)是一种常见的功能性疾病,中医病名为"肠郁"。郭朋教授根据IBS生理、病理特点,以疏肝健脾法调和肝脾,辨证施治,取得良好疗效。文章从病因病机、辨证论治及经典案例介绍等几个方面对郭教授治疗IBS经验进行系统阐述,以期为中医药治疗IBS提供理论和方法学参考。 相似文献
42.
43.
44.
45.
46.
47.
《European journal of surgical oncology》2019,45(12):2353-2359
IntroductionMajor hepatectomy (MH) is often needed in the curative management of intrahepatic cholangiocarcinoma (IHCC) and colorectal liver metastases (CRLM). While similar outcomes could be expected after MH for IHCC and CRLM, outcomes seem worse after MH for IHCC. A better understanding of such differences might help improving perioperative outcomes but comprehensive analysis are lacking.MethodsAll patients undergoing curative intent MH for IHCC or CRLM from 2003 to 2009 were included from two dedicated multi-institutional datasets. Preoperative management and short-term outcomes after MH were first compared. Independent predictors of postoperative mortality and morbidity were identified.ResultsAmong 827 patients, 333 and 494 patients underwent MH for IHCC and CRLM, respectively. Preoperative portal vein embolization was more frequently performed in the CRLM group (p < 0.001). MH in the IHCC group required more extended resection (p < 0.001). Postoperative mortality and severe morbidity rates were significantly higher in the IHCC group (7.2% vs. 1.2% and 29.7% vs. 11.1%, p < 0.001, respectively). Main causes for mortality were postoperative liver failure and deep surgical site infection. MH for IHCC was an independent risk factor for mortality (p < 0.001) and severe morbidity (p < 0.001). After propensity score matching (212 patients in each group), the aforementioned differences regarding outcomes remained statistically significant.ConclusionThis study suggests that IHCC patients are inherently more at risk after MH as compared to CRLM patients. Considering that postoperative liver failure was the most frequent cause of death, preoperative planning might have been inadequate in the setting of IHCC while more complex/extended resections should be expected. 相似文献
48.
目的 探讨采用改良的Sugiura术治疗肝硬化并发门脉高压症患者的疗效及其对门脉血流动力学指标的影响。方法 回忆性分析2013年5月~2015年5月期间我院治疗的56例肝硬化并发门脉高压症患者的临床资料,手术前后采取玻璃管水柱法测量自由门静脉压(FPP),采用吲哚氰绿15分钟潴留率(ICGR15)检测肝脏储备功能,计算肝脏有效血流(ELBF),使用B超检测门脉内径、门静脉血流量(PVF)、肝动脉血流(HAF)和肝总血流量(THF)的变化。结果 经过改良的Sugiura术治疗,56例患者手术成功,出现肺部感染和胸腔积液4例,切口感染2例,门静脉血栓形成5例,吻合口狭窄4例,胃瘘1例。经充分引流、营养支持、抗感染、补充白蛋白或输注血浆等对症支持治疗,病情逐步缓解或痊愈;术后FPP水平为(21.3±3.4) cmH2O,显著低于术前水平【(32.5±5.0)cmH2O,P<0.05】;在术后,56例患者EHBF、THF和PVF水平分别为(0.5±0.1) ml/min、(1481.1±354.0) ml/min和(1046.1±258.0) ml/min,在术后3 m,分别为(0.5±0.3)ml/min、(1574.1±326.0) ml/min和(1131.0±304.1) ml/min,均显著低于术前水平 [分别为(0.7±0.3) ml/min、(1891.0±392.1) ml/min和(1523.1±291.1)ml/min,P<0.05];术后HAF水平为 (435.0±142.1) ml/min,术后3 m时为(443.0±183.1) ml/min,均显著高于术前水平【(368.1±139.1)ml/min,P<0.05】;术后患者ICGR15为(22.7±7.9)%, 显著高于术前的(19.3±5.5)%,差异显著(F=7.327,P<0.05);手术前后门静脉内径变化差异无统计学意义(P>0.05);术后1 m和术后3 m,患者血清白蛋白水平大幅升高【分别为(35.2±2.3) g/L和(36.8±1.7) g/L对(31.8±1.7) g/L,P<0.05】;在术后1 m时,患者外周血PLT和WBC计数分别为(144.5±7.2)×109/L和(13.8±0.6)×109/L,在术后3 m时则分别为(98.1±10.6)×109/L和(4.2±0.8)×109/L,均显著高于术前水平【分别为(75.3±6.7)×109/L和(3.4±0.3)×109/L,P<0.05】。结论 采用改良的Sugiura术治疗肝硬化并发门脉高压症患者能够改善肝功能、血细胞和门脉系统血流动力学指标,降低门静脉压力,对防治病情恶化和消化道出血有帮助,其远期疗效还有待观察。 相似文献
49.
Filippo Pietrantonio Christian Cotsoglou Giovanni Fucà Salvatore Lo Vullo Federico Nichetti Massimo Milione Jorgelina Coppa Marta Vaiani Alessandra Alessi Michele Prisciandaro Michele Droz-Dit Busset Federica Morano Salvatore Corallo Silvia Lazzati Maria Antista Alessia Mennitto Giovanni Randon Alessandra Raimondi Vincenzo Mazzaferro 《Clinical colorectal cancer》2019,18(1):34-43.e6
Background
In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.Patients and Methods
This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Patients received 5 preoperative and 4 postoperative cycles of biweekly COI-B (irinotecan 180 mg/m2 and bevacizumab 5 mg/Kg on day 1, oxaliplatin 85 mg/m2 on day 2, and capecitabine 1000 mg/m2 twice a day on days 2 to 6). The primary endpoint was pathologic response rate in the intention-to-treat population. A Simon 2-stage design was adopted to detect an increase from 30% to 50% with a power of 90%. Dynamic imaging biomarkers (early tumor shrinkage [ETS], deepness of response, maximum standardized uptake volume [SUVmax]/regression index) and next generation sequencing data were explored as surrogates.Results
From June 2013 to March 2017, 46 patients were enrolled. Pathologic response was achieved in 63% patients (endpoint met), and responders achieved significantly better survival outcomes with respect to non-responders. The most frequent grade 3/4 adverse events were diarrhea and neutropenia (8.7%) in the preoperative phase and thromboembolic events (5.9%) in the postoperative phase. ETS and lower SUV-2 were significantly associated with pathologic response.Conclusion
The COI-B regimen is a feasible and highly active perioperative strategy in patients with molecularly unselected, potentially resectable CRCLM. ETS and SUV-2 have a promising role as imaging-based biomarkers for pathologic response. 相似文献50.
陈永节 《中国继续医学教育》2020,(2):123-124
目的分析在乙型肝炎后肝硬化治疗中采用核苷类药物的治疗价值。方法将本院在2018年1月—2019年2月期间收治的乙型肝炎后肝硬化患者68例纳入研究,以奇偶法均分为两组,对照组(34例)行常规治疗方案,观察组(34例)行核苷类药物治疗,对比两组乙型肝炎后肝硬化患者的治疗效果。结果对照组HBeAg转阴率14.71%低于观察组44.12%,P<0.05差异有统计学意义。观察组临床指标(ALT、AST、TBIL、ALB、PTA、Child-Pugh)优于对照组患者,P<0.05差异有统计学意义。观察组并发症发生率8.82%低于对照组并发症发生率为41.18%,P<0.05差异有统计学意义。结论在乙型肝炎后肝硬化治疗中采用核苷类药物可以取得显著的治疗效果,可以有效改善患者的临床症状,提升患者的转阴率,安全性较高。 相似文献